Ward, Jane L., Wu, Yanqi, Harflett, Claudia, Onafuye, Hannah, Corol, Delia, Lomax, Charlotte, Macalpine, William J., Cinatl Jr., Jindrich, Wass, Mark N., Michaelis, Martin, and others. (2020) Miyabeacin: A new cyclodimer presents a potential role for willow in cancer therapy. Scientific Reports, 10 . E-ISSN 2045-2322. (doi:10.1038/s41598-020-63349-1) (KAR id:81106)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/3MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.1038/s41598-020-63349-1 |
Abstract
Willow (Salix spp.) is well known as a source of medicinal compounds, the most famous being salicin, the progenitor of aspirin. Here we describe the isolation, structure determination, and anti-cancer activity of a cyclodimeric salicinoid (miyabeacin) from S. miyabeana and S. dasyclados. We also show that the capability to produce such dimers is a heritable trait and how variation in structures of natural miyabeacin analogues is derived via cross-over Diels-Alder reactions from pools of ortho-quinol precursors. These transient ortho-quinols have a role in the, as yet uncharacterised, biosynthetic pathways around salicortin, the major salicinoid of many willow genotypes.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1038/s41598-020-63349-1 |
Uncontrolled keywords: | Secondary metabolism; solution-state NMR |
Subjects: | R Medicine > RM Therapeutics. Pharmacology |
Divisions: | Divisions > Division of Natural Sciences > Biosciences |
Depositing User: | Martin Michaelis |
Date Deposited: | 04 May 2020 10:36 UTC |
Last Modified: | 05 Nov 2024 12:46 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/81106 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):